0A43 Stock Overview
A biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Inovio Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.11 |
| 52 Week High | US$12.27 |
| 52 Week Low | US$1.42 |
| Beta | 1.41 |
| 1 Month Change | 21.05% |
| 3 Month Change | -5.15% |
| 1 Year Change | -80.78% |
| 3 Year Change | -90.52% |
| 5 Year Change | n/a |
| Change since IPO | -98.71% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0A43 | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 10.2% | -0.4% | 1.1% |
| 1Y | -80.8% | -14.8% | 0.8% |
Return vs Industry: 0A43 underperformed the UK Biotechs industry which returned -14.8% over the past year.
Return vs Market: 0A43 underperformed the UK Market which returned 0.8% over the past year.
Price Volatility
| 0A43 volatility | |
|---|---|
| 0A43 Average Weekly Movement | 9.6% |
| Biotechs Industry Average Movement | 9.2% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in GB Market | 11.1% |
| 10% least volatile stocks in GB Market | 3.2% |
Stable Share Price: 0A43's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0A43's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1983 | 134 | Jacqueline Shea | www.inovio.com |
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial.
Inovio Pharmaceuticals, Inc. Fundamentals Summary
| 0A43 fundamental statistics | |
|---|---|
| Market cap | US$75.92m |
| Earnings (TTM) | -US$96.48m |
| Revenue (TTM) | US$283.10k |
Is 0A43 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0A43 income statement (TTM) | |
|---|---|
| Revenue | US$283.10k |
| Cost of Revenue | US$70.80m |
| Gross Profit | -US$70.51m |
| Other Expenses | US$25.96m |
| Earnings | -US$96.48m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.63 |
| Gross Margin | -24,908.02% |
| Net Profit Margin | -34,079.58% |
| Debt/Equity Ratio | 0% |
How did 0A43 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/20 01:43 |
| End of Day Share Price | 2025/05/20 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Inovio Pharmaceuticals, Inc. is covered by 20 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Aydin Huseynov | Benchmark Company |
| Geoffrey Meacham | BofA Global Research |
| Jonathan Aschoff | Brean Capital |